Encompass Health Corporation (NYSE:EHC) Receives $143.86 Average PT from Analysts

Shares of Encompass Health Corporation (NYSE:EHC) have received an average recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $143.8571.

EHC has been the topic of several analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. TD Cowen initiated coverage on shares of Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 price target on the stock. Leerink Partners set a $152.00 price target on shares of Encompass Health in a research report on Friday, May 22nd. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Barclays dropped their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th.

Encompass Health Stock Performance

NYSE EHC opened at $99.13 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The firm’s fifty day moving average price is $104.35 and its two-hundred day moving average price is $104.47. Encompass Health has a 1 year low of $92.77 and a 1 year high of $127.99. The firm has a market capitalization of $9.83 billion, a P/E ratio of 16.55, a price-to-earnings-growth ratio of 2.21 and a beta of 0.72.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm posted $1.37 earnings per share. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, research analysts anticipate that Encompass Health will post 5.97 EPS for the current year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 annualized dividend and a dividend yield of 0.8%. Encompass Health’s dividend payout ratio is presently 12.69%.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the transaction, the executive vice president directly owned 24,755 shares of the company’s stock, valued at $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Encompass Health

Several large investors have recently modified their holdings of the stock. EP Wealth Advisors LLC raised its position in shares of Encompass Health by 2.4% in the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock valued at $453,000 after purchasing an additional 88 shares during the period. Allworth Financial LP raised its position in shares of Encompass Health by 14.7% in the third quarter. Allworth Financial LP now owns 701 shares of the company’s stock valued at $89,000 after purchasing an additional 90 shares during the period. Gamco Investors INC. ET AL raised its position in shares of Encompass Health by 2.0% in the first quarter. Gamco Investors INC. ET AL now owns 4,813 shares of the company’s stock valued at $466,000 after purchasing an additional 94 shares during the period. Gibson Capital LLC raised its position in shares of Encompass Health by 4.3% in the first quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock valued at $235,000 after purchasing an additional 101 shares during the period. Finally, Leuthold Group LLC raised its position in shares of Encompass Health by 0.3% in the fourth quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock valued at $3,308,000 after purchasing an additional 104 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.